Hikma Pharmaceuticals PLC
HKMPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,127 | $2,875 | $2,517 | $2,553 |
| % Growth | 8.8% | 14.2% | -1.4% | – |
| Cost of Goods Sold | $1,712 | $1,468 | $1,279 | $1,252 |
| Gross Profit | $1,415 | $1,407 | $1,238 | $1,301 |
| % Margin | 45.3% | 48.9% | 49.2% | 51% |
| R&D Expenses | $141 | $149 | $144 | $143 |
| G&A Expenses | $568 | $638 | $509 | $488 |
| SG&A Expenses | $568 | $638 | $509 | $488 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $94 | $253 | $303 | $88 |
| Operating Expenses | $803 | $1,040 | $956 | $719 |
| Operating Income | $612 | $367 | $282 | $582 |
| % Margin | 19.6% | 12.8% | 11.2% | 22.8% |
| Other Income/Exp. Net | -$158 | -$86 | -$49 | -$39 |
| Pre-Tax Income | $454 | $281 | $233 | $543 |
| Tax Expense | $93 | $89 | $42 | $124 |
| Net Income | $359 | $190 | $188 | $421 |
| % Margin | 11.5% | 6.6% | 7.5% | 16.5% |
| EPS | 3.24 | 1.7 | 1.68 | 3.64 |
| % Growth | 90.6% | 1.2% | -53.8% | – |
| EPS Diluted | 3.22 | 1.72 | 1.68 | 3.62 |
| Weighted Avg Shares Out | 111 | 111 | 112 | 116 |
| Weighted Avg Shares Out Dil | 112 | 111 | 113 | 117 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $7 | $3 | $30 |
| Interest Expense | $88 | $87 | $70 | $69 |
| Depreciation & Amortization | $197 | $191 | $190 | $167 |
| EBITDA | $727 | $559 | $688 | $766 |
| % Margin | 23.2% | 19.4% | 27.3% | 30% |